Adhera Therapeutics
Data Collection & Internet Portals · Louisiana, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
8000 Innovation Park Dr, Baton Rouge, Lo...Phone Number
(919) 518-3748Website
www.adherathera.comRevenue
<$5 MillionStock Symbol
ATRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Adhera Therapeutics
Adhera Therapeutics Inc. is an emerging specialty pharmaceutical company that develops and commercializes innovative fixed-dose combination therapies and integrated care delivery systems to improve treatment outcomes for patients with chronic and acute diseases in the United States. The company's primary focus is on hypertension and resistant hypertension management, with plans to expand into additional therapeutic areas. At the foundation of Adhera's strategy is the Total Care System (TCS), a proprietary integrated platform designed to enhance treatment efficacy, patient adherence, and clinical outcomes by coordinating pharmaceutical products, digital health technologies, and patient support services. The centerpiece of this ecosystem is DyrctAxess, Adhera's patented technology platform engineered to provide enhanced efficiency, control, and access to clinical information that empowers patients, physicians, and manufacturers to achieve optimal care coordination. Adhera's lead productRead more
Adhera Therapeutics Org Chart
SM
Territory Manager
HK
Assistant Manager
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adhera Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Adhera Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Adhera Therapeutics
Adhera Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Adhera Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Adhera Therapeutics recently announced quarterly report
Check if Adhera Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Adhera Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Adhera Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Adhera Therapeutics
Compare insights from companies similar to Adhera Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Adhera Therapeutics is experiencing very low activity levels compared to other companies in the Media & Internet sector.
What does this means?
Adhera Therapeutics is drawing exceptional interest within the Media & Internet industry, suggesting notable developments or strong market momentum, learn more about Adhera Therapeutics.
Adhera Therapeutics Tech Stack
A closer look at the technologies used by Adhera Therapeutics
Most Recent Scoops
Executive Move
Board of Directors
Left Company
Executive Move
Board of Directors
Lateral Move
Executive Move
Executive Move
As previously announced, Zahed Subhan, Chief Executive Officer, has assumed the role of Chairman for the Board of Directors.
Promotion
Executive Move
Adhera Therapeutics News & Media
Adhera Therapeutics' CEO, board member leaving - Business North Carolina
A Durham-based biotech company announced its CEO and a board member are leaving the operation.Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that the Company is to commence a dose finding study of MLR-1023 (tolimidone) in Type 1 Diabetes in collaboration with the Alberta Diabetes Institute (“ADI”) at the University of Alberta (“U of A”), located in Edmonton, Alberta, Canada.Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company’s Board of Directors (the “Board”) appointed Zahed Subhan PhD MBA JD as Chief Executive Officer of Adhera Therapeutics, effective September 30, 2022. The same day, Dr. Subhan was elected to serve as Chairman of the Board. Dr. Subhan has been serving as aAdhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021.
Read more news
Top Data Collection & Internet Portals Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adhera Therapeutics
Sign Up For FreeTo access detailed company insights
Adhera Therapeutics Inc. is an emerging specialty pharmaceutical company that develops and commercializes innovative fixed-dose combination therapies and integrated care delivery systems to improve treatment outcomes for patients with chronic and acute diseases in the United States. The company's primary focus is on hypertension and resistant hyper... Read More
